BERLIN, Aug. 5 (Xinhua) -- German pharmaceutical company BioNTech announced on Monday that it incurred a net loss of 1.12 billion euros (1.23 billion U.S. dollars) in the first half of this year, as the company shifts its focus toward cancer treatments following a decline in COVID-19 vaccine sales.
In the second quarter alone, the deficit amounted to 807.8 million euros, significantly higher than the 190.4 million euros loss recorded in the same quarter last year.
